It’s notoriously tough for experimental psychiatric drugs to succeed in clinical tests. BlackThorn Therapeutics wants to show that an AI-driven, precision approach can make it easier, and today it’s added another $76 million to get the chance to prove it. The new Se...
Alector, a company taking an immunotherapy approach to Alzheimer’s disease and other brain disorders, has raised approximately $176 million in an initial public offering. The South San Francisco, CA, biotech sold 9.25 million shares Wednesday evening priced at $19 api...
DIYBio is a hot term these days, as more so-called citizen scientists gain access to biotechnology tools and “biohacker” lab spaces. But how about DIY drug discovery? Independent scientist Ethan Perlstein is trying to prove it’s possible. After a year ...